SynthesisJournal of cancer research and clinical oncology2017

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.

Verena S Hoffmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.